Digital as the Differentiator for Biopharma and Medtech

Digital as the Differentiator for Biopharma and Medtech

With the Inflation Reduction Act now on the books, the U.S. Centers for Medicare & Medicaid Services (CMS) will begin negotiating drug prices with the pharmaceutical industry. That, combined with other headwinds such as increased competition from me-too drugs, and ever-present pricing pressure from payers, means that pharma players now more than ever need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.
Learning from the auto industry Almost every industry has had to confront a fundamental existential question: What is our product? Consider the automotive industry, which once was largely about hardware…

Continue Reading
How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19 [Sponsored]

How to Leverage Diagnostic Development to Guard Against RSV, Flu and Covid-19 [Sponsored]

For the first two years of the Covid-19 pandemic, healthcare professionals focused on understanding the Covid-19 virus, how best to guard against it, and developing tests to detect it. They also tracked, aggregated, and analyzed health data to assess and monitor the public health threat on a regional, state and country-wide level. In the longer term, vaccine development and distribution were used to slow the spread to avoid a collapse of the health system and to reduce the potency of the virus for the majority of people.
More recently, attention has shifted to the long perceived threat of viruses coming together with…

Continue Reading